Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial
Microbial Genomics · 18.05.2026 · 12 (5)
DOI: 10.1099/mgen.0.001721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Genomics, erschienen am 18.05.2026. Verfasst von Belson M Kutambe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi. Hauptthemen laut MEDLINE: Genome, Bacterial, Salmonella typhi, Typhoid Fever, Typhoid-Paratyphoid Vaccines. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Wellcome Trust, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background
Salmonella enterica serovar Typhi ( S . Typhi), the causative agent of typhoid fever, continues to pose a major public health challenge in many low- and middle-income countries. The World Health Organization recommended typhoid conjugate vaccine (TCV) use in countries with a high burden of disease and/or high rates of antimicrobial resistance (AMR). Recent introductions of TCVs into national immunization programmes are expected to substantially reduce this burden. However, the impact of vaccine introduction on pathogen populations has not been widely investigated.
Methods
To fill this research gap, we analysed the genomes of isolates from a trial in Malawi. A Phase 3, double-blind, randomized, controlled trial enrolled 28,130 healthy children aged 9 months through 12 years of age to receive either TCV (Typbar-TCV, Bharat Biotech) or meningococcal A conjugate vaccine (MenA). We conducted Illumina whole-genome sequencing and compared isolates from the TCV intervention arm to the MenA control arm with regard to (i) S . Typhi lineage distribution, (ii) AMR profile, (iii) mutations in genes associated with Vi capsule biosynthesis and expression and (iv) phylogenetic population structure.
Results
We obtained high-quality genome sequences for 136 S . Typhi isolates (24 from the TCV arm, 112 from the MenA arm). Of these, 135 (99%) belonged to lineage L4.3.1.1.EA1. Isolates from the two arms were intermixed across multiple sub-clades. Nearly all isolates (135 out of 136) carried genes encoding resistance to ampicillin, cotrimoxazole and chloramphenicol. Non-synonymous mutations in the quinolone resistance determining region were identified in five isolates (three GyrA S83F; two GyrA S464F), and no statistically significant difference in prevalence of these mutations was observed between study arms (Fisher’s exact test, P =0.25). Mutations in Vi capsule–associated genes were detected in 11 out of 112 (9%) MenA isolates and 1 out of 24 (4%) TCV isolates (Fisher’s exact test, P =0.67). Fifteen MenA cases were hospitalized, two of whom had Vi-associated mutations. In one of these cases, the Vi mutation has previously been associated with increased virulence in a murine model; however, there was no significant association between tested Vi mutations and hospitalization ( P >0.91).
Conclusions
We identified no clinically meaningful genomic differences between S . Typhi isolates from participants vaccinated with TCV or MenA, and no Vi-negative S . Typhi were detected. These findings suggest no detectable short-term evolutionary impact of TCV on circulating S . Typhi populations in this Phase 3 trial. However, given the limited follow-up period and S . Typhi’s relatively slow substitution rate, continued genomic surveillance in this population after national TCV introduction in 2023 is essential to detect evolutionary responses to vaccine pressure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
- Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
- Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK.
- MM Global Health, Zurich Switzerland and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, Scotland, UK.
Förderung
- National Institute for Health and Care Research
- Wellcome Trust
- Bill and Melinda Gates Foundation
Zitieren
APA
Kutambe, B. M., Patel, P. D., Chizani, K., Silungwe, N., Kukacha, C., Carey, M. E., Meiring, J. E., Laurens, M. B., Gordon, M. A., & Ashton, P. M. (2026). Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial. Microbial Genomics, 12(5). https://doi.org/10.1099/mgen.0.001721
Vancouver
Kutambe BM, Patel PD, Chizani K, Silungwe N, Kukacha C, Carey ME, et al. Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial. Microbial Genomics. 2026;12(5). doi:10.1099/mgen.0.001721
BibTeX
@article{Kutambe2026,
author = {Kutambe, Belson M and Patel, Priyanka D and Chizani, Kenneth and Silungwe, Niza and Kukacha, Christopher and Carey, Megan E and Meiring, James E and Laurens, Matthew B and Gordon, Melita A and Ashton, Philip M},
title = {Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial},
journal = {Microbial Genomics},
year = {2026},
volume = {12},
number = {5},
doi = {10.1099/mgen.0.001721}
}
EUVIMED